Why ImmunityBio Stock Is Up More Than 11% Today

Shares of biopharma outfit ImmunityBio (IBRX +11.16%) are rising firmly again today, following through on last week's effort to rekindle the erratic rally that's been underway since early January. As of 3:15 p.m. ET Monday, in fact, shares are up 11.2%, mostly in response to late last week's announcement that Macau's regulatory body has approved the company's oncology drug Anktiva® for certain forms of bladder cancer. It is believed that this approval will open the door to approvals in other countries in an ...